Pharmaceutical firm Cytogen has received a notice of compliance from Health Canada for its ProstaScint prostate cancer imaging agent, allowing the Princeton, NJ-based vendor to begin selling the radiolabeled monoclonal antibody agent in Canada.
In both Canada and the U.S., ProstaScint is indicated in newly diagnosed prostate cancer patients who are at high risk for lymph node metastases and for recurrent prostate cancer patients who are suspected of having occult metastatic disease following a radical prostatectomy. In Canada, ProstaScint is also indicated for use in identifying recurrent prostate cancer patients who are likely to benefit from receiving local salvage radiation therapy, according to Cytogen.
By AuntMinnie.com staff writersMarch 18, 2002
Related Reading
Cytogen revenues rise, February 13, 2002
Cytogen raises $8 million, January 23, 2002
Cytogen trims loss in Q3, November 7, 2001
Cytogen net loss widens in Q2 despite revenue gains, August 7, 2001
Cytogen builds executive team, June 11, 2001
Copyright © 2002 AuntMinnie.com
